Madrigal Pharmaceuticals, Inc. hired a world-renowned liver specialist to protect the integrity of the clinical trials for its only drug. When he warned that the data behind the drug could not be verified, Madrigal pushed him out, according to a whistleblower lawsuit filed in federal court in Chicago. Jeff and his law firm filed the case.
Read the complaint here.
The lawsuit has drawn coverage from leading pharmaceutical industry outlets in the United States and abroad, including STAT News, Fierce Pharma, Endpoints News, and Scrip, the London-based pharmaceutical industry publication. Fierce Pharma reported that Madrigal’s stock fell 8% on November 3, the same day the company reported 50% year-over-year sales growth and roughly $1.1 billion in sales so far this year. Analysts at Citi tied the drop to the lawsuit. Madrigal denies the allegations and stands by the drug’s safety. A jury will decide the truth.
Madrigal Hires a Leading Doctor to Guard Its Only Drug
Dr. Michael Charlton is a hepatologist, a doctor who treats liver disease. In October 2024, he left his post as medical director of University of Chicago Medicine’s Transplant Institute to become Madrigal’s Senior Vice President and Head of Clinical Development.
Madrigal sells one drug, Rezdiffra, the first drug approved to treat a serious liver disease called MASH. According to the complaint, Rezdiffra brings in essentially all of Madrigal’s revenue. The FDA granted the drug an accelerated but conditional approval. Madrigal’s future depends on winning full approval.
Dr. Charlton supervised the testing that would be used to obtain full FDA approval. That meant he was responsible for keeping patients in the studies safe, making sure the science was sound, and making sure the results Madrigal reported to the FDA and to investors were accurate.
Warnings to Leadership About Liver Injuries
Dr. Charlton started raising alarms almost immediately. Shortly after he arrived, according to the complaint, Madrigal asked him to evaluate several patients whose livers had begun to fail after they started taking Rezdiffra.
According to the complaint, he told senior executives that Madrigal was mishandling cases of possible liver injury in its own studies. Some cases of possible liver injury were never sent for the independent review the trials required.
The complaint alleges that reports written by treating doctors were edited to shift the cause of liver failure away from the drug and toward the patients’ underlying disease. In one case, a Madrigal Board member who had sought information that could reveal whether a patient was getting the drug or a placebo then asked to remove that patient, who had developed a life-threatening liver complication, from an ongoing Phase 3 trial.
In February 2025, Dr. Charlton ran an analysis of the FDA’s public database of reported drug side effects. On the measures that signal liver harm, Rezdiffra ranked higher than every other drug he tested.
He presented the results to the CEO and other senior leaders. According to the complaint, nobody in the room expressed concern for patient safety. A Senior Vice President of Clinical Operations complained that the analysis had been run at all, saying it “put the company at risk.”
The Numbers Don’t Add Up, and the CEO Says “Stop Looking”
According to the complaint, Madrigal prepared a presentation on two-year results for the annual meeting of the European Association for the Study of the Liver. The Chief Medical Officer ordered a quality check. It found that almost none of the numbers matched the raw patient data. Every error made the drug look better than the data supported.
On May 11, 2025, Dr. Charlton told the CEO, in front of the CFO and the head of investor relations, that the key findings still could not be confirmed in the raw patient data. According to the complaint, the CEO told him to “Stop looking.”
Madrigal allegedly presented the disputed data at the European meeting over Dr. Charlton’s documented objections and then repeated it to investors.
Five Weeks Later, Madrigal Pushes Him Out
Five weeks after the “stop looking” meeting, Madrigal told Dr. Charlton he was being removed from his role. Madrigal framed it as a promotion. It was not. The complaint alleges that Madrigal cut him out of meetings, took away his direct reports, removed him from the review of clinical publications, and stripped him of the work he was hired to do.
While he was on leave, Madrigal told him he would be replaced. It removed him as chair of the committee that reviews the company’s trial plans and gave him a title with no leadership, no supervisory authority, and no role in his field.
Madrigal gave Dr. Charlton’s Head of Clinical Development job to a colleague who, according to the complaint, has no experience in liver disease.
He Won’t Put His Name on the Data
Dr. Charlton filed a complaint with the U.S. Department of Labor in December 2025.
In January 2026, Dr. Charlton was scheduled to speak at a major international scientific meeting. According to the complaint, speaking as a Madrigal employee meant delivering a Madrigal-approved presentation and vouching for the same results he had told the company, and told the Department of Labor, could not be verified and might be fraudulent. He refused.
“Every scientist knows the rule. You do not put your name on data you cannot verify,” said Jeffrey R. Kulwin, his lawyer. “Madrigal put Dr. Charlton in a position to break that rule. He refused, and the company forced him out.”
On January 5, 2026, Dr. Charlton resigned. The complaint alleges he was constructively discharged, meaning Madrigal made the job so intolerable that a reasonable person would have felt forced to quit.
The Law Protects Employees Who Speak Up
The lawsuit brings a claim under the whistleblower protections of the Sarbanes-Oxley Act, 18 U.S.C. Section 1514A. That law protects employees of public companies who report conduct they reasonably believe is defrauding shareholders. In general, employees need to show only that their belief was reasonable and that the report played a role in how they were treated.
The case is Michael Charlton, M.D. v. Madrigal Pharmaceuticals, Inc., No. 1:26-cv-12410, filed in the United States District Court for the Northern District of Illinois.
Did something change at work after you reported misconduct? Contact Jeff.
NOTICE: The information in this post comes from allegations in a legal complaint and a court ruling filed in the public record. This is a contested matter. The defendants are expected to deny the allegations, and no court or jury has decided whether they are true as of the date of this post.







